These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10022540)

  • 21. Chimeric Antigen Receptor T-Cell Therapies Advancing.
    Brower V
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27920051
    [No Abstract]   [Full Text] [Related]  

  • 22. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.
    Poirot L; Philip B; Schiffer-Mannioui C; Le Clerre D; Chion-Sotinel I; Derniame S; Potrel P; Bas C; Lemaire L; Galetto R; Lebuhotel C; Eyquem J; Cheung GW; Duclert A; Gouble A; Arnould S; Peggs K; Pule M; Scharenberg AM; Smith J
    Cancer Res; 2015 Sep; 75(18):3853-64. PubMed ID: 26183927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Moving from tinkering in the garage to assembly line production: the manufacture of genetically modified T cells expressing chimeric antigen receptors (CARs) comes on line.
    Cooper LJ
    Cancer Gene Ther; 2015 Mar; 22(2):64-6. PubMed ID: 25675874
    [No Abstract]   [Full Text] [Related]  

  • 24. Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers.
    Tay JC; Zha S; Wang S
    Immunotherapy; 2017 Dec; 9(16):1339-1349. PubMed ID: 29185393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
    Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
    Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.
    Holzinger A; Abken H
    Cancer Immunol Immunother; 2017 Nov; 66(11):1505-1507. PubMed ID: 28755091
    [No Abstract]   [Full Text] [Related]  

  • 27. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.
    Gilham DE; Debets R; Pule M; Hawkins RE; Abken H
    Trends Mol Med; 2012 Jul; 18(7):377-84. PubMed ID: 22613370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adoptive therapy with CAR redirected T cells for hematological malignancies.
    Li S; Yang Z; Shen J; Shan J; Qian C
    Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.
    Li K; Lan Y; Wang J; Liu L
    Tumour Biol; 2017 Mar; 39(3):1010428317692229. PubMed ID: 28347250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safer CARS.
    Heslop HE
    Mol Ther; 2010 Apr; 18(4):661-2. PubMed ID: 20357776
    [No Abstract]   [Full Text] [Related]  

  • 31. A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial.
    Mayor M; Zeltsman M; McGee E; Adusumilli PS
    Immunotherapy; 2016 May; 8(5):491-4. PubMed ID: 27140404
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
    Suzuki M; Curran KJ; Cheung NK
    Pediatr Blood Cancer; 2015 Aug; 62(8):1326-36. PubMed ID: 25832831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency.
    Wang W; Ma Y; Li J; Shi HS; Wang LQ; Guo FC; Zhang J; Li D; Mo BH; Wen F; Liu T; Liu YT; Wang YS; Wei YQ
    Gene Ther; 2013 Oct; 20(10):970-8. PubMed ID: 23636245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishing guidelines for CAR-T cells: challenges and considerations.
    Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.
    Chicaybam L; Sodré AL; Bonamino M
    Int Rev Immunol; 2011; 30(5-6):294-311. PubMed ID: 22053970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.
    Feldman SA; Assadipour Y; Kriley I; Goff SL; Rosenberg SA
    Semin Oncol; 2015 Aug; 42(4):626-39. PubMed ID: 26320066
    [No Abstract]   [Full Text] [Related]  

  • 39. Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging.
    Liu K; Liu X; Peng Z; Sun H; Zhang M; Zhang J; Liu S; Hao L; Lu G; Zheng K; Gong X; Wu D; Wang F; Shen L
    Oncotarget; 2015 Sep; 6(27):23735-47. PubMed ID: 26124178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Promise of Chimeric Antigen Receptor T-Cell Therapy.
    Frey NV; Porter DL
    Oncology (Williston Park); 2016 Oct; 30(10):880-8, 890. PubMed ID: 27744645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.